The National Institute of Genomic Medicine (INMEGEN) was established in 2004 by the Promotional Consortium of the National Institute of Genomic Medicine. The consortium, created in 2001, was comprised by the National Autonomous University of Mexico, the National Council for Science and Technology, the Ministry of Health and the Mexican Health Foundation. Today, INMEGEN is the national leader in genomic research for medical applications seeking to improve health in Mexico. Its main objectives are: developing scientific research projects with cutting edge technology, training human resources of excellence; and generating genomic innovations and applications to improve health care in compliance with universal ethical principles and respect for human rights.
Genomic medicine is gaining momentum. The general director of the institute founded in 2004 explains how genomics is helping unlocking the secret codes, which will help understand and treat pathologies…
Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet…
Eduardo Gonzalez Pier, former Vice-Minister for Integration and Development of the Health Sector, shares his perspective on current dynamics in Mexico’s public health sector and highlights how collaboration between private…
Alvaro Angel, the recently appointed general manager of the pharmaceutical division of Bayer Mexico, provides insights into the rapidly evolving local pharma market, and documents Bayer Mexico’s ambitious growth strategy;…
Cédric Ertlé, managing director at Laboratoires Expanscience Mexico, explains the strategy that the affiliate has implemented to obtain 20 and 45 percent of growth in dermocosmetics and rheumatology respectively and…
Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most…
José Angel García Hinojosa, counsellor of the board of the Grupo Loeffler Russek, details how Loeffler’s impressive growth has forced the company to increase their manufacturing capacity. While Loeffler grew…
Dr. David Kershenobich Stalnikowitz, General Director of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán on the myriad issues surrounding diabetes in Mexico and how the Mexican healthcare…
Consuelo Albarrán, co-founder and CEO of DEFI Latina Healthcare, showcases the increasing added value brought by this leading Cofepris-authorized third party (ATP) to the pharmaceutical industry, the recent expansion of…
Rodrigo Puga, the recently appointed general manager of Pfizer Mexico, documents his strategic priorities to further strengthen the company’s performance in Mexico and consolidate Pfizer’s leadership within the Mexican market…
General Manager of Merck Mexico, Pedro Galvis, showcases the strategic importance of the Mexican affiliate within Merck’s global network and explains the importance of public-private partnerships in enhancing patient access and…
Paulina Escobedo, general manager of B. Braun Medical Mexico, provides insights into the impressive development of this division since it was set up in the country in 2011, while the…
The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI…
See our Cookie Privacy Policy Here
